S-1/A: QT Imaging Holdings Files S-1/A, Details Capital Raises

QT Imaging Holdings, Inc. filed an S-1/A registration statement detailing recent private placements, debt restructuring, and its strategy for commercializing breast imaging technology.

Summary

• QT Imaging Holdings, Inc. (formerly GigCapital5, Inc.) is a medical device company focused on innovative body imaging systems using low energy sound, with its primary product being the QT Breast Scanner.
• The company completed a reverse stock split at a 3:1 ratio, effective October 23, 2025, and is seeking to relist on the Nasdaq Capital Market.
• Recent financing activities include a $10.1 million senior secured term loan from Lynrock Lake Master Fund LP on February 26, 2025, which was increased to $15.1 million on August 26, 2025, with Tranche B of $5.0 million repaid on October 6, 2025.
• Three private placements were completed in 2025, raising aggregate gross proceeds of approximately $18,880,655: $500,000 on April 9, 2025, $200,000 on May 12, 2025, and $18,180,655 on October 3, 2025.
• The company extinguished obligations under the Yorkville Note and Cable Car Note on February 26, 2025, using proceeds from the Lynrock Lake Term Loan.
• QT Imaging has entered into an exclusive distribution agreement with NXC Imaging, Inc. for the U.S. market, with minimum order quantities (MOQs) of $18.0 million for 2025 and $27.0 million for 2026.
• A manufacturing agreement with Canon Medical Systems Corporation (CMSC) was signed on March 28, 2025, appointing CMSC as the exclusive manufacturer of QT Breast Scanners for NXC distribution.
• An exclusive distribution agreement with Gulf Medical Co. (GMC) was signed on August 21, 2025, for Saudi Arabia, with MOQs of $11.2 million to $12.3 million in 2026.
• The company reported a net loss of $19,694,921 for the nine months ended September 30, 2025, compared to $5,496,958 for the same period in 2024.
• Revenue increased to $10,649,930 for the nine months ended September 30, 2025, from $4,032,168 for the same period in 2024, primarily due to increased scanner sales.
• The company continues to incur significant operating losses and negative cash flows, with an accumulated deficit of $51,635,448 as of September 30, 2025.
• The QT Breast Scanner is FDA-cleared as a supplementary imaging device, not a replacement for screening mammography, and the company aims for future clearances for breast cancer screening and as an alternative to breast MRI.

Sentiment

Score: 3

Explanation: While the company shows strong revenue growth and strategic partnerships, the significant increase in net losses and continued negative cash flow from operations, coupled with a large accumulated deficit, indicates substantial financial challenges and a high-risk profile. The reliance on continuous capital raises and the early stage of commercialization for its core product contribute to a cautious outlook.

Positives

• Significant revenue growth for the nine months ended September 30, 2025, with revenue increasing by $6,617,762 (164%) to $10,649,930, driven by increased QT Breast Scanner sales.
• Secured substantial financing through a $10.1 million senior secured term loan from Lynrock Lake, later increased to $15.1 million, and private placements totaling over $18.8 million.
• Established key strategic partnerships: an exclusive U.S. distribution agreement with NXC Imaging (a Canon Medical USA subsidiary) with binding minimum order quantities (MOQs) for 2025 ($18.0M) and 2026 ($27.0M).
• Entered into an exclusive manufacturing agreement with Canon Medical Systems Corporation (CMSC) for QT Breast Scanners, providing scale manufacturing capabilities and favorable 90-day payment terms.
• Expanded international market reach with an exclusive distribution agreement with Gulf Medical Co. for Saudi Arabia, targeting $11.2 million to $12.3 million in MOQs for 2026.
• Successfully extinguished prior debt obligations, including the Yorkville Note and Cable Car Note, reducing financial complexity and potentially improving the balance sheet structure.
• The QT Breast Scanner is FDA-cleared as an ultrasonic imaging system, offering non-ionizing radiation, no compression, and no contrast dyes, providing a safer and more comfortable patient experience.
• The company is actively pursuing regulatory pathways for expanded indications, including breast cancer screening and as an alternative to breast MRI, which could significantly expand its market opportunity.
• Development of a biomarker-driven Cloud SaaS platform is underway, aiming to transition from a hardware company to a precision imaging AI platform, potentially offering strong long-term gross margins through recurring revenue.

Negatives

• Incurred significant net losses, with a net loss of $19,694,921 for the nine months ended September 30, 2025, a substantial increase from $5,496,958 in the prior year period.
• Experienced negative cash flow from operations, using $5,857,572 for the nine months ended September 30, 2025, indicating continued reliance on external financing.
• Accumulated deficit grew to $51,635,448 as of September 30, 2025, highlighting a history of unprofitability and the need for significant future revenue generation.
• Gross margin slightly decreased in the nine months ended September 30, 2025, due to variability in weighted-average inventory costs.
• The company operates in a highly competitive medical imaging industry with larger, well-established competitors possessing greater resources and market share.
• The success of the business model is highly dependent on achieving widespread market acceptance of the QT Breast Scanner, which is currently a supplementary device and not a replacement for screening mammography.
• The company faces risks related to obtaining adequate reimbursement and insurance coverage from third-party payors for its imaging services, which is crucial for commercial success.
• The stock is currently traded on the OTC Market OTCQB Venture Market tier, which is less liquid and can lead to greater price volatility, and the company is seeking to relist on Nasdaq.
• The company is highly dependent on key members of its executive management team, and the loss of these individuals could impede business plans and growth strategies.
• The company has limited experience in large-scale contract manufacturing and is dependent on a single critical supplier for ultrasound transducer subcomponents, posing supply chain risks.
• The terms of the Lynrock Lake Term Loan include restrictive covenants and mandatory repayment triggers, which could limit operational flexibility and require prepayments under certain conditions.

Risks

• Incurring significant operating losses and potentially never achieving or maintaining profitability.
• Limited operating history with current offerings makes it difficult to evaluate future business prospects.
• Inability to attract new customers on a cost-effective basis.
• Failure to successfully execute growth initiatives, business strategies, or operating plans.
• Forecasts and projections may prove incorrect or inaccurate, leading to actual results differing materially.
• Failure to attract and retain qualified personnel, including key executives.
• Inability to evolve the business model from a hardware company to a biomarker-driven Cloud SaaS platform.
• Reliance on internet infrastructure, third-party data center providers, and own systems, with potential for failures or interruptions.
• Failure to successfully develop or introduce new and enhanced products that achieve market acceptance.
• QT Breast Scanner and future products may not achieve widespread market acceptance, hindering revenue generation.
• Inability to successfully execute the business model on a global scale, including obtaining necessary regulatory approvals.
• Negative impact on imaging service utilization due to recent changes in U.S. payment policies for imaging procedures.
• Need to incur additional indebtedness or seek new equity/debt financings, which may not be available on favorable terms or cause dilution.
• Debt agreements contain restrictions that may limit operational flexibility.
• High dependence on the successful development, marketing, and sale of the breast imaging device and other products still in development.
• Inability to obtain additional clearances or approvals from the FDA and other regulatory agencies worldwide, or delays in receiving them.
• Highly competitive industry subject to rapid technological change, potentially rendering current technology obsolete.
• Dependence on third parties to manufacture products and supply component parts, leading to risks of increased costs, quality issues, or delays.
• Development or manufacturing problems, higher costs, or delays could limit revenue or increase losses.
• Additional regulatory burdens and risks associated with global business expansion.
• Inability to obtain adequate reimbursement or insurance coverage from third-party payors.
• Billing complexities associated with obtaining payment or reimbursement may negatively affect revenue, cash flow, and profitability.
• Key supplier or distribution agreements may not be successful, or anticipated benefits may not be realized.
• Product liability claims, product recalls, and warranty claims could be expensive, divert management attention, and harm business reputation.
• Products may cause or contribute to adverse medical events or be subject to failures/malfunctions requiring FDA reporting, leading to sanctions.
• Lack of business interruption insurance or other insurance (except D&O, property, product liability) could lead to uninsured losses.
• Mishandling of sensitive information or data security breaches could harm business, reputation, or lead to litigation.
• Computer system failures, cyber-attacks, or cybersecurity deficiencies could disrupt operations and lead to losses.
• Uncertain and rapidly evolving laws and regulations related to health data and health information technology.
• Significant tariffs or trade restrictions could materially harm revenue and results of operations.
• Impact of changes in general economic conditions, including adverse economic conditions or catastrophic events.
• Technological change may adversely affect sales and cause products to become obsolete.
• Inability to sustain revenue growth or profitability.
• Marketing efforts, including social media, may expose the company to additional regulatory scrutiny.
• Extensive government regulation could restrict development, marketing, sale, and distribution of products.
• Failure to comply with post-marketing regulatory requirements could lead to enforcement actions.
• Limited experience in identifying and working with large-scale medical device manufacturers.
• Obtaining and maintaining patent protection is difficult and costly, and may not ensure protection.
• Claims that technology or products infringe third-party intellectual property rights could result in costly litigation.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Claims that employees, consultants, or advisers wrongfully used or disclosed trade secrets of former employers.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Rights to develop and commercialize products may be subject to terms and conditions of third-party licenses and sublicenses.
• Required payment of milestones and royalties under license agreements.
• Licensing technology to third parties could result in disputes or limit future operations.
• Highly dependent on key members of executive management team; inability to retain them could impede business plan.
• Management team has limited experience managing a public company, leading to potential inefficiencies and increased time devoted to compliance.
• Certain directors and/or officers may have competing interests.
• Increased costs and demands upon management as a public company.
• Unanticipated changes in effective tax rates or adverse outcomes from tax examinations.
• Only significant asset is ownership interest in QT Imaging, Inc., which may not be sufficient to pay dividends or satisfy other financial obligations.
• Price of common stock may be volatile or decline regardless of operating performance.
• No intention to pay dividends on common stock for the foreseeable future.
• If securities analysts do not publish research or issue unfavorable reports, stock price could decline.
• Issuance of additional shares or convertible securities could dilute ownership and adversely affect stock price.
• Future sales, or perception of future sales, of common stock could cause market price to decline.
• Public warrants may never be in the money and may expire worthless; terms may be amended adversely.
• Company may redeem unexpired public warrants prior to exercise at a disadvantageous time.
• Warrants accounted for as a warrant liability, with changes in fair value reported in earnings, may adversely affect stock price.
• Trading on OTCQB Venture Market tier is volatile and sporadic, impacting stock price and liquidity.
• Inability to enforce covenants not to compete, allowing competitors to benefit from former employees' expertise.
• Inability to attract and retain highly skilled employees.
• Industry data, projections, and estimates are inherently uncertain and may be inaccurate.
• Market opportunity estimates may prove inaccurate.
• Required write-downs or write-offs, restructuring, and impairment charges could negatively affect financial condition and stock price.
• Exchange rate fluctuations and inflation may negatively affect results of operations, and hedging may not be successful.

Future Outlook

The company anticipates continued losses and negative cash flows in the foreseeable future as it invests in product development, clinical trials, and manufacturing. Future capital requirements depend on growth rate, R&D spending, sales and marketing expansion, and new product introductions. Management believes current cash and expected revenues from distribution agreements will fund operations for at least the next 12 months. The company aims to expand regulatory clearances for breast cancer screening and as an alternative to breast MRI, and to build a biomarker-driven Cloud SaaS platform.

Management Comments

• "Medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable and accessible."
• "Our goal is to improve global health outcomes through the development and commercialization of imaging devices that address critical healthcare challenges with accuracy and precision."
• "Our use of the words safe, safety, effectiveness, and efficacy in relation to the QT Breast Scanner in this Management's Discussion and Analysis and all other documents related to us is limited to the context of the Section 510(K) Summary of Safety and Effectiveness that was reviewed and responded to by the FDA."
• "Management believes that the additional cash received for the Lynrock Lake Term Loan and from the October 2025 Private Placement, as well as the additional revenue from MOQs per the Amended Distribution Agreement and the Gulf Medical Distribution Agreement, will be sufficient to fund the Company’s current operating plan for at least the next 12 months."

Industry Context

The medical imaging market is large ($40 billion worldwide, $10 billion in U.S.) and growing, with global cancer screening expected to reach $472 billion by 2033. The breast imaging market alone is estimated at $4.6 billion in 2023 with an 8% CAGR, driven by non-ionizing segments. QT Imaging's non-ionizing, non-compression, non-contrast dye technology positions it to address shortcomings of traditional mammography and MRI, particularly for dense breasts and younger women. The company aims to disrupt the market by offering a safer, more affordable, and accessible alternative, especially in low-resource environments and for direct-to-consumer/practitioner applications. However, it faces intense competition from established players like General Electric, Siemens, Philips, and Hologic.

Comparison to Industry Standards

• QT Breast Scanner offers superior performance compared to traditional mammogram with respect to specificity (false positives), potentially reducing unnecessary invasive follow-up procedures and costs.
• The technology provides a lower price point than conventional high-energy imaging equipment (CT, MRI).
• Unlike mammography, QT Breast Scanner uses no ionizing radiation or compression, and unlike MRI, it requires no contrast dyes, offering a safer and more comfortable patient experience.
• The QT Breast Scanner provides sub-millimeter, high-definition, 3D image resolution, enabling identification of normal and abnormal breast structures and precise location of findings, which is a significant increase in diagnostic information compared to handheld ultrasound.
• The technology uniquely quantifies breast density using transmission information, which is a risk factor for breast cancer, a capability not fully matched by traditional methods.
• Clinical studies suggest QTscan improves non-cancer recall rates without substantially affecting cancer recall rates, and its ROC-AUC improved significantly by 10% compared to FFDM.
• The proposed QT Orthopedic Scanner aims to offer faster, in-office, and same-day orthopedic imaging without the need for dedicated facilities with magnetic field shielding or liquid helium supply, unlike MRI or CT.
• Visual Grading Analysis studies comparing QTscan to MRI for knee imaging showed QTscan images were equivalent or better than MRI in over 90% of reviewed knee structure images, with higher contrast.
• The proposed QT Infant Scanner addresses limitations of current infant imaging (CT's radiation risk, MRI's sedation requirement) by offering a non-ionizing, non-anesthesia, open-environment solution, with piglet studies showing comparable or superior detail to 3-Tesla MRI.

Management Changes

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company was not a party to any material legal proceedings.

Related Party Transactions

• Dr. Raluca Dinu (CEO and Director) and Dr. Avi Katz (Chairman) are married to each other and participated in the April 2025 Private Placement, purchasing shares and warrants.
• Dr. Avi Katz is the sole manager of GigAcquisitions5, LLC, the founding stockholder, and holds a 50% membership interest in GigManagement, LLC.
• Dr. John Klock (Director) previously operated QT Imaging Center (the Practice), which had a Management Services Agreement and Space and Equipment Sublease Agreement with the company, both terminated as of December 31, 2024, due to his retirement.
• The company entered into a Data Use and License Agreement with the Practice on April 3, 2024, granting a license to use de-identified health information for research.
• The company issued convertible notes (2020 Notes) to three stockholders in July 2020, with an outstanding amount of $3,190,112 as of September 30, 2025.
• A Working Capital Note of $705,000 was issued to a stockholder, outstanding as of September 30, 2025.
• The November 2024 Private Placement included Dr. Avi Katz, Dr. Raluca Dinu, GigAcquisitions5, LLC, Ross Taylor, Zeev Weiner, Daniel Dickson, and an affiliate of James Greene as purchasers.
• Lynrock Lake Master Fund LP, a related party, provided a $10.1 million senior secured term loan and received the Lynrock Lake Warrant; it also participated in the First Amendment to the Credit Agreement.
• The Yorkville Note and SEPA were with YA II PN, Ltd. (Yorkville), which was repaid with proceeds from the Lynrock Lake Term Loan and the issuance of the Yorkville Warrant, which was later repurchased by the company.
• The Cable Car Note was with Funicular Funds, LP (Cable Car), which was repaid with proceeds from the Lynrock Lake Term Loan.
• The October 2025 Private Placement was led by Sio Capital Management, LLC, which is an accredited investor.

Stakeholder Impact

• **Shareholders:** Dilution from recent and future equity financings, including private placements and warrant exercises. Potential for stock price volatility due to market conditions, company performance, and large number of shares registered for resale. The reverse stock split aims to improve market perception and Nasdaq relisting eligibility.
• **Patients:** Potential for safer, more comfortable, and accessible breast imaging without ionizing radiation or compression. Future products like orthopedic and infant scanners aim to address unmet medical needs and improve diagnostic experiences.
• **Healthcare Providers (Hospitals, Clinics, Radiologists):** Opportunity to adopt innovative imaging technology that offers superior specificity and potentially lower costs compared to traditional methods. Requires training for radiologists to interpret QT Breast Scanner images. Reimbursement policies will significantly impact adoption.
• **Employees:** Continued investment in R&D and commercialization efforts may lead to job growth. However, the company's history of losses and need for additional capital could create job insecurity if financial targets are not met. Management changes, such as the new CFO, could impact internal operations.
• **Distribution Partners (NXC, Gulf Medical Co.):** Exclusive distribution agreements provide significant revenue opportunities through MOQs. Success is tied to the company's ability to manufacture and deliver products, and regulatory approvals in respective territories.
• **Suppliers (Canon Medical Systems Corporation):** The manufacturing agreement with CMSC provides a stable revenue stream for CMSC and ensures production capacity for QT Imaging. Dependence on a limited number of critical suppliers for components poses risks to QT Imaging's production.
• **Creditors (Lynrock Lake):** Secured debt agreements provide a first priority lien on company assets, offering protection. Mandatory repayment triggers and financial covenants impose obligations on the company, impacting its financial flexibility.

Next Steps

• Relist common stock on the Nasdaq Capital Market.
• Continue to improve high quality, high resolution, native 3D, reproducible image quality of breast imaging technology.
• Build a biomarker-driven Cloud SaaS platform combining hardware, software, and cloud-based artificial intelligence modules.
• Perform scale manufacturing internally and partner strategically for large-scale manufacturing.
• Expand the market by supporting additional Direct-to-Consumer (DTC) and Direct-to-Practitioner (DTP) approaches.
• Leverage intellectual property to develop other scanning medical imaging products, such as infant scanners and full-body scanners.
• Pursue regulatory and commercial pathways for the QT Breast Scanner as an alternative to breast MRI in screening younger women at above-average risk for breast cancer.
• Engage in continuing research on the clinical efficacy of QTscan images and develop key opinion leaders (KOLs).
• Navigate the economics and price controls of the U.S. reimbursement system and foreign countries.
• Collect data from installed QT Breast Scanners to support reimbursement and expanded FDA clearances.
• Tailor marketing efforts towards patients and medical professionals/radiologists as the installed base expands.
• Continue to use unlisted CPT code 76999 in 2025 for payer education and reimbursement.
• Seek hospital outpatient reimbursement under the Medicare Outpatient Prospective Payment System (OPPS) by applying for a New Technology Ambulatory Payment Classification (New Tech APC) in September 2025, aiming for a C code in January 2026.
• Apply for a Category III CPT code from the American Medical Association (AMA) in November 2025, aiming for use in January 2027.
• Begin regulatory approval process with the Saudi FDA (SFDA) and United Arab Emirates FDA (UAE FDA).
• Intend to obtain a CE Mark in the European Union in 2026.
• Develop the Open Partial Angle Scanner concept for orthopedic and infant medical imaging markets.
• Company will introduce at least one new product improvement per year to the Equipment (QT Breast Scanners) and timely correct all Equipment bugs or other defects as necessary to address performance issues, as per the Amended Distribution Agreement with NXC.

Key Dates

Recommendation

QT Imaging Holdings presents a high-risk, high-reward profile. The company has demonstrated significant revenue growth and secured crucial strategic partnerships for manufacturing and distribution, which are positive indicators for future commercialization. The innovative, non-ionizing imaging technology addresses a large market with clear advantages over traditional methods. However, the substantial and increasing net losses, persistent negative cash flow from operations, and a large accumulated deficit raise significant concerns about long-term viability without sustained capital raises. The stock's current trading on the OTCQB Venture Market tier, despite efforts to relist on Nasdaq, adds to volatility and liquidity risks. While the potential for disruptive technology is compelling, the financial performance and ongoing need for external funding suggest a 'hold' recommendation for seasoned investors, awaiting clearer signs of sustained profitability and successful market penetration before considering a 'buy'. The recent capital raises provide short-term liquidity, but the path to self-sufficiency remains challenging.

Keywords

Medical Imaging, Breast Scanner, Ultrasound Technology, QT Breast Scanner, FDA Clearance, Medical Device, Healthcare Technology, Diagnostic Imaging, Non-ionizing Imaging, 3D Ultrasound, SaaS Platform, Artificial Intelligence, Machine Learning, Corporate Finance, Private Placement, Debt Financing, SEC Filing, S-1/A, Public Company, OTC Markets, Nasdaq Relisting, Canon Medical Systems, NXC Imaging, Gulf Medical Co., Risk Factors, Warrants, Stock Split, Financial Performance, Operating Losses, Capital Raise